Iovance Biotherapeutics, Inc. IOVA Operating Lease Liabilities (Total)
Operating Lease Liabilities (Total) at other companies
Other financials
Where this comes from
Reported directly by Iovance Biotherapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseLiability.
The official record: Iovance Biotherapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Iovance Biotherapeutics, Inc.'s operating lease liabilities (total).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Iovance Biotherapeutics, Inc.'s operating lease liabilities (total)?
- Iovance Biotherapeutics, Inc. (IOVA) reported operating lease liabilities (total) of $46.78M in Q1 2026.
- How has Iovance Biotherapeutics, Inc.'s operating lease liabilities (total) changed year-over-year?
- Iovance Biotherapeutics, Inc.'s operating lease liabilities (total) decreased by 11.3% year-over-year, from $52.72M to $46.78M.
- What is the long-term trend for Iovance Biotherapeutics, Inc.'s operating lease liabilities (total)?
- Over 5 years (2020 to 2025), Iovance Biotherapeutics, Inc.'s operating lease liabilities (total) has grown at a -1.3% compound annual growth rate (CAGR), from $51.66M to $48.44M.
- What does operating lease liabilities (total) mean?
- This represents the total present value of future lease payments for operating leases, recognized as a liability on the balance sheet. It reflects the company's long-term commitment to leased assets such as office space, warehouses, and equipment. Tracking this helps investors evaluate the company's off-balance-sheet financing obligations and overall debt-like commitments.